With one CNS program in Phase II and four more approaching the clinic’s doorstep, Cerevance has raised the first $45 million of a series B round that could reach $60 million -- although the COVID-19...

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...

Takeda will grant neurology newco Cerevance a license to preclinical and clinical CNS programs and provide the company with lab space and personnel from Takeda's former operations in Cambridge, U.K. Cerevance launched in December with...

Neurology newco Cerevance LLC (Cambridge, Mass.) launched with $36 million, including a $21.5 million series A from co-leaders Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Lightstone Ventures. Cerevance declined to name the source of the balance,...

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring up its...

Takeda and Scripps expanded a 2010 discovery deal to include additional undisclosed targets in new undisclosed therapeutic areas. The partners are using the institute's high throughput screening technology to discover compounds against undisclosed targets from...

After first making a venture investment in Envoy Therapeutics Inc. in 2009 and then sampling its wares under a 2010 target discovery deal, Takeda Pharmaceutical Co. Ltd. has taken the next step and acquired the...

Takeda will acquire partner Envoy for up to $140 million in cash, including an upfront payment and preclinical milestones. Takeda, which has a 12.5% stake in Envoy, will gain the biotech's bacTRAP technology and preclinical...